Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory Routine +

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Positions for Psychedelic Boom Amidst Regulatory Survival Risks

By The Northwire Desk — AI Analysis Apr 20, 2026 · 08:31 NUMI · 0.05 NUMINUS WELLNESS INC. J
Executive Summary
  • Most Recent News (2026-04-20): Numinus Wellness responded to a U.S. Executive Order directing federal agencies to accelerate research and regulatory review for psychedelic therapies (psilocybin, ibogaine, MDMA, LSD). The company is positioning its Cedar Clinical Research (CCR) sites and practitioner training divisions to address infrastructure bottlenecks like therapist supply and site readiness.
  • Historical Context (2026-03-13): Management reported completion of a strategic transformation involving the sale of U.S. wellness clinics and wind-down of non-operating subsidiaries. Crucially, the company is working to complete its 2025 audit to lift a BCSC cease-trade order (CTO) and address a TSX delisting review initiated in November 2025.
  • Operational Status: The company has trained >2,500 practitioners and supported >20 psychedelic drug development studies. However, the Annual General Meeting for the year ended Aug 31, 2025 was not held by the Feb 28, 2026 deadline.
  • Financial Outlook: Management is evaluating financing options, strategic partnerships, and potential M&A to bolster the balance sheet after audit completion.
Material Impact
  • Sector Tailwind vs. Company Solvency: The Executive Order represents a significant positive catalyst for the broader psychedelic sector, potentially increasing demand for clinical trial sites and training services where Numinus operates. However, this news does not materially resolve the immediate existential risks highlighted in March (CTO, Delisting Review, Audit Completion).
  • Expectation vs. Reality: The response is consistent with previous strategic pivots announced in March (focusing on clinical trials/training rather than direct wellness clinics). It confirms management's narrative but adds no new financial data or resolution to the listing status issues.
  • Market Reaction Potential: Given the stock price has been stagnant at $0.05 for over a year, indicating severe liquidity constraints or OTC trading status, positive sector news is unlikely to trigger a significant breakout without concurrent confirmation of audit completion and CTO removal. The impact is incremental rather than transformative regarding share value in the immediate term.
NUMI · Price
Company Overview
  • Company: Numinus Wellness Inc. operates in the psychedelic therapy ecosystem.
  • Flagship Projects:
    • Cedar Clinical Research (CCR): Specialized clinical trial site network capable of ~200 dosing sessions annually, supporting drug developers moving through accelerated approval timelines.
    • Practitioner Training Platform: Education division contracted to deliver therapist training for active Phase 3 trials; >2,500 practitioners trained to date.
  • Strategic Shift: Moved away from direct U.S. wellness clinics (sold) toward B2B services supporting drug development and infrastructure readiness (training/sites).
Read the original news release →

More from NUMINUS WELLNESS INC. J

Mar 13, 2026 · 17:01

Numinus Wellness Provides Corporate Update

Production / Operations